Atrion Corporation (ATRI) Shares Sold by Bronfman E.L. Rothschild L.P.
Bronfman E.L. Rothschild L.P. cut its position in Atrion Corporation (NASDAQ:ATRI) by 3.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 2,958 shares of the medical instruments supplier’s stock after selling 120 shares during the period. Bronfman E.L. Rothschild L.P. owned approximately 0.16% of Atrion Corporation worth $1,903,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Capital Analysts LLC bought a new position in Atrion Corporation during the second quarter worth approximately $434,000. Neuberger Berman Group LLC boosted its position in Atrion Corporation by 7.4% in the second quarter. Neuberger Berman Group LLC now owns 82,894 shares of the medical instruments supplier’s stock worth $53,326,000 after buying an additional 5,695 shares during the last quarter. Prudential Financial Inc. boosted its position in Atrion Corporation by 583.6% in the second quarter. Prudential Financial Inc. now owns 4,970 shares of the medical instruments supplier’s stock worth $3,197,000 after buying an additional 4,243 shares during the last quarter. Victory Capital Management Inc. boosted its position in Atrion Corporation by 17.7% in the second quarter. Victory Capital Management Inc. now owns 438 shares of the medical instruments supplier’s stock worth $282,000 after buying an additional 66 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in Atrion Corporation by 4,800.0% in the second quarter. BNP Paribas Arbitrage SA now owns 196 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 192 shares during the last quarter. Hedge funds and other institutional investors own 59.72% of the company’s stock.
Atrion Corporation (NASDAQ ATRI) traded up 1.47% on Thursday, hitting $623.00. 213 shares of the stock were exchanged. The firm has a market cap of $1.15 billion, a PE ratio of 34.91 and a beta of 0.91. Atrion Corporation has a 52-week low of $393.95 and a 52-week high of $691.95. The stock’s 50 day moving average price is $634.69 and its 200 day moving average price is $548.27.
Atrion Corporation (NASDAQ:ATRI) last released its earnings results on Tuesday, August 8th. The medical instruments supplier reported $5.40 earnings per share for the quarter. Atrion Corporation had a return on equity of 18.67% and a net margin of 22.75%. The firm had revenue of $36.16 million for the quarter. Equities research analysts forecast that Atrion Corporation will post $9.90 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 29th. Stockholders of record on Friday, September 15th will be issued a $1.20 dividend. This represents a $4.80 dividend on an annualized basis and a dividend yield of 0.78%. This is an increase from Atrion Corporation’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, September 14th. Atrion Corporation’s dividend payout ratio (DPR) is 23.52%.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/atrion-corporation-atri-shares-sold-by-bronfman-e-l-rothschild-l-p/1534246.html.
Separately, BidaskClub upgraded shares of Atrion Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 29th.
In other news, Chairman Emile A. Battat sold 100 shares of the firm’s stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $585.50, for a total value of $58,550.00. Following the transaction, the chairman now directly owns 149,081 shares in the company, valued at approximately $87,286,925.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Chairman Emile A. Battat sold 699 shares of the firm’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $580.84, for a total value of $406,007.16. Following the completion of the transaction, the chairman now owns 149,480 shares in the company, valued at $86,823,963.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 2,016 shares of company stock worth $1,150,994. Company insiders own 24.23% of the company’s stock.
Atrion Corporation Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.